Antidepressants: Life threatening placebos?;Antidepressiva: Lebensgefährliche plazebos?

PsychoNeuro

Volumn 31, Issue 10, 2005, Pages 480-484

  Fritze, Jürgen ^a   Aldenhoff, Josef B ^a   Bergmann, Frank ^a   Maier, Wolfgang ^a   Möller, Hans Jürgen ^a  

^a Psychotherapie und Nervenheilkunde (DGPPN)   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; LITHIUM; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; HUMAN; MEDICAL LITERATURE; META ANALYSIS; PSYCHOPHARMACOLOGY; PUBLICATION; RESEARCH ETHICS; REVIEW; RISK FACTOR; SUICIDE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW;

EID: 27944490285     PISSN: 16119991     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-922235     Document Type: Review

References (38)

1. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: A meta-analysis of efficacy and tolerability. J Affective Disord 2000; 58: 19-36
2. Anderson IM, Haddad P. Clinical trials of antidepressant medications are producing meaningless results - Against. Br J Psychiatry 2003; 183: 102-104
3. Baldessarini RJ, Tondo L, Hennen J. Lithium treatment and suicide risk in major affective disorders: update and new findings. J Clin Psychiatry 2003; 64 (Suppl 5): 44-52
4. th, 2002, http://journals.apa.org/prevention/ volume5/pre0050026c.html
5. Cipriani A, Barbui C, Geddes JR. Suicide, depression, and antidepressants. BMJ 2005; 330: 373-374
6. Entsuah R, Huang H, Willard L Venlafaxine and SSRIs: pooled remission analysis (Mega-analysis of 31 studies of > 7000 patients). Poster bei: World Congress of Psychiatry (WCP) 2002, 24.-29. August; Yokohama, Japan
7. Fergusson D, Doucette S, Cranley Glass K, Shapiro S, Healy D, Hebert P, Hutton B. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005; 330: 396-402
8. Fritze J. The Adrenergic-Cholinergic Imbalance Hypothesis of Depression: A Review and a Perspective. Rev Neurosci 1993; 4: 63-93
9. Fritze J, Lanczik M, Sofic E, Struck M, Riederer P. Cholinergic neurotransission seems not to be involved in the category depression but possibly in personality. J Psychiatry Neurosci 1995; 20: 39-48
10. Fritze J, Möller H-J. Design of clinical trials of antidepressants: should a placebo arm be included? CNS Drugs 2001; 15: 755-764
11. Fritze J. Nicht-selektive Monoamin-Rückaufnahme-Inhibitoren: Neurochemie, Wirkmechanismus. In: Riederer P, Laux G, Pöldinger W (eds.). Neuro-Psychopharmaka, Vol 3: Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer. Heidelberg, Springer, 2002: 120-138
12. Fritze J, Schneider B, Weber B. Venlafaxin ist kein SSRI, sondern ein SNRI, und das ist relevant. Psychoneuro 2003; 29: 240-244
13. Fritze J. Psychopharmaka-Verordnungen: Ergebnisse und Kommentare zum Arzneiverordnungsreport 2004. Psychoneuro 2005; 31: 46-52
14. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361: 653-661
15. th, 2002, http://journals.apa.org/prevention/volume 5/pre0050027c.html
16. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005; 330: 385-389
17. Guo B, Scott A, Bowker S: Suicide Prevention Strategies. Evidence from Systematic Reviews. Alberta Heritage Foundation for Medical Research, HTA 28: Health Technology Assessment, ISBN 1-896956-68-8, 2003
18. Hansen L. A critical review of akathisia, and its possible association with suicidal behaviour. Hum Psychopharmacol 2001; 16: 495-505
19. Hintikka J, Pesonen T, Saarinen P, Tanskanen A, Lehtonen J, Viinamaki H. Suicidal ideation in the Finnish general population. A 12-month follow-up study. Soc Psychiatry Psychiatr Epidemiol 2001; 36: 590-594
20. Jureidini JN, Doecke C, Mansfield R, Haby M et al. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004; 328: 879-883
21. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: An analysis of the Food and Drug Administration database. J C Psychopharmacology 2002; 22: 40-45
22. th, 2002, http://journals. apa.org/prevention/volume5/pre0050023a .html
23. th, 1998, http://journals.apa.org/pre vention/volume1/pre0010002a.html
24. th, 1998, http://journals.apa.org/prevention/ volume1/pre0010006c.html
25. Maier W, Möller H-J Metaanalyses - highest level of empirical evidence? Eur Arch Psychiatry Clin Neurosci (in press)
26. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, Evans S, Gunnell D. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 330 (2005) 389-395
27. Möller HJ. Antidepressants - do they decrease or increase suicidality? Pharmacopsychiatry 1992; 25: 249-253
28. Moncrieff J, Wessely S, Hardy R. Metaanalysis of trials comparing antidepressants with active placebos. Br J Psychiatry 1998; 172: 227-231
29. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. The Cochrane Database of Systematic Reviews 2004
30. Oeljeschläger B, Müller-Oerlinghausen B. Wege zur Optimierung der individuellen antidepressiven Therapie. Deutsches Ärzteblatt 2004; 101: A1337-A1340
31. Quitkin FM, Rabkin JG, Gerald J, Davis JM, Klein DF. Validity of clinical trials of antidepressants. Am J Psychiatry 2000; 157: 327-337
32. Smith D, Dempster C, Glanville J, Free-mantle N, Anderson I. Efficacy and tolerability of venlafaxine with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. British Journal of Psychiatry 2002; 180: 396-494
33. Storosum JG, Elferink AJA, van Zwieten BJ, van den Brink W, Gersons BPR, van Strik R, Broekmans AW. Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. European Neuropsychopharmacology 2001; 11: 173-180
34. Thase M, Entsuah A, Rudolph R. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234-241
35. th, 2002, http://journals.apa. org/prevention/volume5/pre0050023c. html
36. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001; 104: 163-172
37. Vitiello B, Swedo S. Antidepressant medications in children. N Engl J Med 2004; 350 (15): 1489-91
38. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: Variable, substantial, and growing. J Am Med Ass 2002; 287: 1840-1847